Cardiovascular Death Essays -- Health, Treatment

Introduction Every year an estimated 184,000 to 400,000 Americans die from sudden cardiovascular death due to left ventricular (LV) systolic dysfunction (Cesario & William Dec, 2006). One of the treatments of choice for the patient with a life-threating ventricular tachyarrhythmia is the automated implantable cardioverter defibrillator (AICD). Studies have shown that the placement of an automated implantable cardioverter defibrillator (AICD) in patients with LV systolic dysfunction significantly reduces overall mortality (Cesario & William Dec, 2006; Henyan et al., 2006). Background and Significance Over the past 20 years the AICD have become more complex due to technological advances and software sophistication. Today, the indication for implantation of the AICD is rapidly expanding (Schoenfeld, 2007). The use of these devices in managing a diverse population of cardiac patients is increasing. The National ICD Registry annual report for 2008 noted that the average age of patients receiving the device was 65 years old and more than 75% of the patients have 1 or more comorbid diseases (Kaufman, R. S., Mueller, S. P., Ottenberg, L. A. & Koening. A. B., 2011; Zhan, C., Baine, B. W., Sedrakyan, A., & Steiner, C., 2007). These factors contribute to the increasing numbers of patients with AICD devices in the United States. In 2008, 339,076 Americans received the device, compared to 75,000 implantations in 2001 and 34,000 in 2000 (Kaufman et al., 2011). The implication for the increasing number of patients with AICDs is that anesthesia providers will be more likely to encounter thi s patient population presenting for elective or emergency surgical procedures. While it is the anesthesia provider’s duty to provide safe and compe... ...mproved dramatically. Due to an aging population, increasing prevalence of cardiovascular disease, and expanding indications for AICD therapy, the number of patients with AICDs presenting for surgery will continue to rise. Areas of concern for the anesthesia provider with this patient population include preoperative device interrogation, perioperative reprogramming, disabling of the antitachydardia function, and post operative device interrogation. While there are currently no set standards in providing anesthesia care for this patient population, the result of this evidence based project demonstrate that patients with AICDs presenting for surgery can be safely cared for during the operative period. It is the responsibility of the anesthesia provider to be aware of the best evidence with regard to patients with AICDs in place that require anesthetic management. Cardiovascular Death Essays -- Health, Treatment Introduction Every year an estimated 184,000 to 400,000 Americans die from sudden cardiovascular death due to left ventricular (LV) systolic dysfunction (Cesario & William Dec, 2006). One of the treatments of choice for the patient with a life-threating ventricular tachyarrhythmia is the automated implantable cardioverter defibrillator (AICD). Studies have shown that the placement of an automated implantable cardioverter defibrillator (AICD) in patients with LV systolic dysfunction significantly reduces overall mortality (Cesario & William Dec, 2006; Henyan et al., 2006). Background and Significance Over the past 20 years the AICD have become more complex due to technological advances and software sophistication. Today, the indication for implantation of the AICD is rapidly expanding (Schoenfeld, 2007). The use of these devices in managing a diverse population of cardiac patients is increasing. The National ICD Registry annual report for 2008 noted that the average age of patients receiving the device was 65 years old and more than 75% of the patients have 1 or more comorbid diseases (Kaufman, R. S., Mueller, S. P., Ottenberg, L. A. & Koening. A. B., 2011; Zhan, C., Baine, B. W., Sedrakyan, A., & Steiner, C., 2007). These factors contribute to the increasing numbers of patients with AICD devices in the United States. In 2008, 339,076 Americans received the device, compared to 75,000 implantations in 2001 and 34,000 in 2000 (Kaufman et al., 2011). The implication for the increasing number of patients with AICDs is that anesthesia providers will be more likely to encounter thi s patient population presenting for elective or emergency surgical procedures. While it is the anesthesia provider’s duty to provide safe and compe... ...mproved dramatically. Due to an aging population, increasing prevalence of cardiovascular disease, and expanding indications for AICD therapy, the number of patients with AICDs presenting for surgery will continue to rise. Areas of concern for the anesthesia provider with this patient population include preoperative device interrogation, perioperative reprogramming, disabling of the antitachydardia function, and post operative device interrogation. While there are currently no set standards in providing anesthesia care for this patient population, the result of this evidence based project demonstrate that patients with AICDs presenting for surgery can be safely cared for during the operative period. It is the responsibility of the anesthesia provider to be aware of the best evidence with regard to patients with AICDs in place that require anesthetic management.